The National Institutes of Health (NIH) announces a unique opportunity for investigators working with small molecule compounds to gain access to a robust virtual pharma drug development network to develop neurotherapeutic drugs. Successful applicants to this FOA will become collaborative participants in this network, receiving both funding and no-cost access to contracted drug development services that are not typically available to the academic research community. Funding will be provided through a U01 cooperative agreement mechanism to conduct biological testing of compound analogs in disease assays and models in the investigators laboratory. No-cost drug development services will also be provided, including medicinal chemistry optimization, IND-directed pharmacology and toxicology, and Phase I clinical testing. Researchers in possession of disease assays and small molecule compounds that show promise for treating nervous system and psychiatric disorders, but that are not yet suitable for clinical testing, are strongly encouraged to apply.